Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074164 | 0.84 | LDHA (0.47) | LDHASRRKDM4EFFAR3TSHR | |
| SCHEMBL28344240 | 0.81 | PLA2G4B (0.38) | LDHASRRFFAR3ALDH1A1TSHR | |
| SCHEMBL1114621 | 0.81 | ALDH1A1 (0.42) | KDM4EPOLBALDH1A1MGAMGAA | |
| SCHEMBL9927497 | 0.80 | KDM4E (0.41) | KDM4EPOLBALDH1A1MGAMGAA | |
| Malonic Acid SCHEMBL7876110 | 0.78 | LDHA (0.56) | LDHASRRFFAR3ALDH1A1MGAM | |
| SCHEMBL11690365 | 0.78 | ALDH1A1 (0.40) | KDM4EPOLBALDH1A1MGAMGAA | |
| SCHEMBL48574 | 0.78 | — | — | |
| SCHEMBL21831931 | 0.78 | ALDH1A1 (0.40) | KDM4EPOLBALDH1A1MGAMGAA | |
| SCHEMBL130115 | 0.78 | MGAM (0.44) | KDM4EPOLBALDH1A1MGAMGAA | |
| SCHEMBL9942104 | 0.78 | HPGD (0.36) | KDM4EPOLBALDH1A1MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200040108-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA | 2020-02-06 | — | — | US | claimed |
| WO-2020026143-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) | 2020-02-06 | — | — | WO | claimed |
| EP-3604346-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | Procter & Gamble International Operations SA (CH) | 2020-02-05 | — | — | EP | claimed |
| CN-107966879-B | Composition for forming silicon-containing extreme ultraviolet resist underlayer film containing additive | 日产化学工业株式会社 | 2021-06-01 | — | — | CN | disclosed |
| CN-104246614-B | Composition for forming silicon-containing extreme ultraviolet resist underlayer film containing additive | 日产化学工业株式会社 | 2020-09-08 | — | — | CN | disclosed |
| US-10730888-B2 | Process for the preparation of dolutegravir | MYLAN LABORATORIES LIMITED (IN) | 2020-08-04 | — | — | US | disclosed |
| US-20200040108-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA | 2020-02-06 | — | — | US | disclosed |
| WO-2020026143-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) | 2020-02-06 | — | — | WO | disclosed |
| EP-3604346-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | Procter & Gamble International Operations SA (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-20180244693-A1 | Process for the preparation of dolutegravir | Mylan Laboratories Ltd. (IN) | 2018-08-30 | — | — | US | disclosed |
| EP-2468740-B1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY DEVICES | JNC CORP (JP) | 2017-08-02 | — | — | EP | disclosed |
| EP-2292610-A1 | Macrolides with VEGF transcription suppression activity | MERCIAN CORPORATION (JP) | 2011-03-09 | — | — | EP | disclosed |
| WO-2011021534-A1 | TETRAHYDROPYRAN COMPOUNDS, LIQUID CRYSTAL COMPOSITIONS AND LIQUID CRYSTAL DISPLAY ELEMENTS | チッソ株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
| US-7667052-B2 | Bioactive substance | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-23 | — | — | US | disclosed |
| EP-2079728-A1 | N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES | Amgen Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | AMGEN INC. | 2008-06-26 | — | — | US | disclosed |
| WO-2008045484-A1 | N-ARYL PYRAZOLE COMPOUNDS FOR USE AGAINST DIABETES | AMGEN INC. (US) | 2008-04-17 | — | — | WO | disclosed |
| US-20060079572-A1 | Novel bioactive substance | MICROBIOPHARM JAPAN CO., LTD. (JP) | 2006-04-13 | — | — | US | disclosed |
| US-7026352-B1 | Physiologically active substances | MERCIAN CORPORATION (JP) | 2006-04-11 | — | — | US | disclosed |
| EP-1380579-A1 | NOVEL PHYSIOLOGICALLY ACTIVE SUBSTANCES | MERCIAN CORPORATION (JP) | 2004-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079572-A1 | Novel bioactive substance | CASP7, MMP7, BMP4 | LDHA 3846/4885SRR 1613/4885KDM4E 4646/4885 |
| US-10730888-B2 | Process for the preparation of dolutegravir | SAMHD1, TYMP, DUT | LDHA 3016/4885SRR 215/4885KDM4E 1195/4885 |
| US-20080153778-A1 | N-aryl pyrazole compounds, compositions, and methods for their use | GLP1R, GPR119, NAT1 | LDHA 2029/4885SRR 3041/4885KDM4E 4209/4885 |
| US-20200040108-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | MGAM, FUT5, FUT6 | LDHA 1504/4885SRR 278/4885KDM4E 2922/4885 |
| US-20180244693-A1 | Process for the preparation of dolutegravir | SAMHD1, TYMP, DUT | LDHA 3016/4885SRR 215/4885KDM4E 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.